Catalent Inc (CTLT)
NYSE NYSE Primary 
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.
Novo Holdings completes $16.5 bln takeover of Catalent
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago.
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
